Home heart monitoring device after discharge for people with heart failure
Tests a home heart-signal device to detect heart failure signs in adults after hospital stay.
Plain-language title generated from the registry record
Registry title: Implementation for Heart Failure Therapies Post-discharge Followed by CardiOSIgnal at HOME
Key facts
- Where
- Monastir and Sousse, TunisiaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who were sent home from the emergency room after an episode of acute heart failure and who have a connected smartphone.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Acute heart failure episode that led to emergency room admission and discharge. LVEF can be above 40% or 40% or below, with at least 1/3 of patients from each group.
- Biomarker or test result
- BNP above 200 pg/ml or NT-ProBNP above 800 pg/ml.
Main reasons for not taking part
- Under 18 years or over 85 years
- Pregnant or breastfeeding women
- History of pulmonary embolism
- Heart or lung problems that a slight chest compression could make worse (for example a pacemaker)
- Known allergy to bisoprolol, ramipril, Entresto, spironolactone, empagliflozine or dapagliflozine
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06944405, who can take part
Where in Tunisia
- Fattouma Bourguiba University Hospital, Emergency departmentMonastir, TunisiaNo longer taking part
- Sahloul Hospital, Emergency departmentSousse, TunisiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Precordior Ltd
- Trial code
- NCT06944405
- Record updated
- 25 April 2025
- Original description
CardioSignal technology (mechanocardiography) could enable home follow-up after admission for acute heart failure, thus improving guidline-directed medical therapies for heart failure dose escalation while reducing the logistical constraints and stress associated with frequent hospital visits. The intended purpose is to detect signs of HF in adults (aged 18 years or older and < 85 years)Read full original descriptionShow less
Implementation for Heart Failure Therapies Post-discharge Followed by CardiOSIgnal at HOME
CardioSignal technology (mechanocardiography) could enable home follow-up after admission for acute heart failure, thus improving guidline-directed medical therapies for heart failure dose escalation while reducing the logistical constraints and stress associated with frequent hospital visits. The intended purpose is to detect signs of HF in adults (aged 18 years or older and < 85 years)
Inclusion: Patients admitted at emergency room for acute heart failure; Patients discharged from emergency room after an episode of acute heart failure; Either LVEF>40% or ≤40%, either known or assessed during the index hospitalization (however at least 1/3 of patients are required from each category); BNP > 200 pg/ml OR NT-ProBNP > 800 pg/ml; Patients with connected smartphone.
Exclusion: Previous history of allergic asthma at an early age; Patients with a history of pulmonary embolism; Cardiorespiratory disorders which may be aggravated by the slight compression of the thorax. (patient with a pacemaker); Known allergies for: bisoprolol, ramipril, Entresto, spironolactone, empagliflozine, dapagliflozine; Patients <18 years and >85 years; Pregnant women. lactating woman; The participant's inability to adhere to study procedures or give informed consent.